Abstract:The present study explores the underlying reasons for the differing outcomes of immunotherapy in lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC), by comparing their immune microenvironments at the single‐cell level. The present study reports two key findings: higher immune activity in LUAD and enhanced extracellular matrix remodeling in LUSC. Background Immune checkpoint blockade has emerged as a key strategy to the therapy landscape of non‐small cell lung cancer (NSCLC). However, notable differences in immunotherapeutic outcomes exist between the two primary NSCLC subtypes: lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). This disparity may stem from the tumor immune microenvironment's heterogeneity at the transcriptome level. Methods By integrative analysis of transcriptomic characterization of 38 NSCLC patients by single‐cell RNA sequencing, the present study revealed a distinct tumor microenvironment (TME) between LUAD and LUSC, with relevant results further confirmed in bulk transcriptomic and multiplex immunofluorescence (mIF) validation cohort of neoadjuvant immunotherapy patients. Results LUAD exhibited a more active immune microenvironment compared to LUSC. This included highly expression of HLA I/II in cancer cells, reinforced antigen presentation potential of dendritic cells and enhanced cytotoxic activity observed in T/NK cells. In LUSC, cancer cells highly expressed genes belonging to the aldo‐keto reductases, glutathione S‐transferases and aldehyde dehydrogenase family, negatively correlating with immunotherapy outcomes in the validation cohort of our center. Further analysis revealed elevated infiltrated cancer‐associated fibroblasts (CAFs) in LUSC, which was corroborated in The Cancer Genome Atlas cohort. Corresponding increased infiltration of ADH1B+ CAFs in major pathologic response (MPR) patients and the higher presence of FAP+ CAFs in non‐MPR patients were demonstrated by multiplex mIF. Moreover, upregulating immunosuppressive extracellular matrix remodeling was identified in LUSC. Conclusions These comprehensive analyses advance the understanding of the differences in TME between LUAD and LUSC, offering insights for patient selection and developing subtype‐specific treatment strategies.

Roles of immune microenvironment heterogeneity in therapy-associated biomarkers in lung cancer.

Heterogeneous Responses in Hepatocellular Carcinoma: the Achilles Heel of Immune Checkpoint Inhibitors.

Heterogeneity of the tumor immune microenvironment and its clinical relevance

Role of Respiratory System Microbiota in Development of Lung Cancer and Clinical Application

Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy

[Advancements in Single-cell RNA Sequencing Technology in the Study of the Tumor Microenvironment in Lung Cancer]

Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy

Role of the tumor immune microenvironment in tumor immunotherapy

Non-immune cell components in tumor microenvironment influencing lung cancer Immunotherapy

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Long Non-Coding RNAs in Lung Cancer: The Role in Tumor Microenvironment

Role of Epigenetics in Lung Cancer Heterogeneity and Clinical Implication.

Heterogeneity of myeloid cells in common cancers: Single cell insights and targeting strategies

Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single‐cell transcriptomic analysis: Implications for distinct immunotherapy outcomes

Lung Cancer Heterogeneity and New Strategies for Drug Therapy.

Immune and non-immune cell subtypes identify novel targets for prognostic and therapeutic strategy: A study based on intratumoral heterogenicity analysis of multicenter scRNA-seq datasets in lung adenocarcinoma

EP16.01-017 T-cell Repertoire Heterogeneity and Homogeneity in Synonymous Multiple Primary Lung Cancers

Applications of single-cell analysis in immunotherapy for lung cancer: Current progress, new challenges and expectations

Heterogeneity of the tumor immune microenvironment and clinical interventions

Causal role of immune cells in lung cancer subtypes: Mendelian randomization study

Heterogeneity of lymphocyte subsets in predicting immune checkpoint inhibitor treatment response in advanced lung cancer: an analysis across different pathological types, therapeutic drugs, and age groups